Frontiers | Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients | Oncology
Pertuzumab and Its Accelerated Approval: Evolving Treatment Paradigms and New Challenges in the Management of HER2-Positive Breast Cancer
Figure 1 | Recent Developments in HER2-Directed Therapy in Breast Cancer | SpringerLink
Cancers | Free Full-Text | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
How PERJETA® (pertuzumab) works for HER2+ Breast Cancer | HCP
Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody - Journal of Biological Chemistry
Precision medicine and personalized breast cancer: combination pertuzu | PGPM
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer | Journal for ImmunoTherapy of Cancer
Pertuzumab is a fully humanized monoclonal antibody based on the human... | Download Scientific Diagram
Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy
References in Evolving novel anti-HER2 strategies - The Lancet Oncology
Dual HER2 blockade with trastuzumab and pertuzumab in HER2-amplified... | Download Scientific Diagram
Mechanisms and Actions of HER2-Targeting Agents in Breast Cancer (Transcript)
Pertuzumab Overview - Creative Biolabs
Pertuzumab in HER2-positive early breast cancer: current use and perspectives | Future Oncology
Proposed Mechanism of Action | PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx)
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism | Breast Cancer Research | Full Text
Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity | Bentham Science
Trastuzumab — Mechanism of Action and Use in Clinical Practice | NEJM
Pertuzumab: new hope for patients with HER2-positive breast cancer - ScienceDirect
Figure 1 from Pertuzumab: Optimizing HER2 Blockade | Semantic Scholar
